Medytox
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Medytox - overview
Established
2000
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in South Korea and founded in 2000, Medy-Tox Inc. operates as a global biopharmaceutical company that focuses on manufacture, research, development of medical compounds. Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc® and Meditoxin®), Medytox reached nearly 40% of market share in Korea since 2009. Medytox Global Business Center is focusing on maximizing synergy through the integrated operation of each business unit, and integrated management of business sites located in Korea and overseas.
Starting from a Taiwan joint venture "Medytox Taiwan", Medy-Tox Inc. established a China joint venture "Medybloom China", a Hong Kong joint venture "Medytox Hong Kong", a Thailand joint venture "MedyCeles", and a 100% owned local subsidiary "MDT International Inc. " in Japan. Medy-Tox Inc.
is currently exporting products to approximately 60 countries. In April 2021, Dominus Investment acquired 399,670 shares in Medytox at KRW 162,634 apiece for KRW 65 billion, in a PIPE transaction. The company's product line includes Botulinum Toxin Type A Products (Meditoxin, INNOTOX and Coretox), Hyaluronic Acid Filler products (Neuramis and Potenfill) and Medical devices (ComfortDual, Neurajet Plus, Recell Ice, Carewave and Careveam) In 2020, Medy-Tox Inc generated KRW 140. 8 billion in sales, a 31.
6% drop from the same period last year. Operating profit from 25. 6 billion won in 2019 turned into an operating loss of KRW 37 billion in 2020. Medytox intends to utilize the capital raised in April 2021 to improve its financial stability.
With the goal of penetrating to the US and Europe, Medy-Tox Inc. plans to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products.
Current Investors
Dominus Investment, ANDA Asset Management, IBK Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.medytox.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Medytox - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 36,262,446,939 | 39,141,030,113 | 75,892,307,994 | 88,505,437,514 | 133,255,671,034 | 181,239,191,116 | 205,444,934,515 | 205,900,275,787 | 140,827,514,747 | 184,869,547,955 | - | - | - |
| % Revenue Growth (YoY) | - | 7.9% | 93.9% | 16.6% | 50.6% | 36.0% | 13.4% | 0.2% | (31.6%) | 31.3% | - | - | - |
| EBITDA (USD) | 18,794,012,710 | 18,626,582,212 | 52,815,555,209 | 55,507,384,619 | 79,921,106,544 | 98,371,715,139 | 101,532,681,447 | 43,829,526,171 | (18,472,059,731) | 52,747,164,252 | - | - | - |
| Operating Income (USD) | 17,034,629,637 | 16,755,929,759 | 49,957,666,153 | 51,662,321,784 | 75,171,894,643 | 90,159,568,055 | 85,485,442,379 | 25,688,754,464 | (37,069,534,839) | 34,491,517,174 | - | - | - |
| Operating Margin | 47.0% | 42.8% | 65.8% | 58.4% | 56.4% | 49.7% | 41.6% | 12.5% | (26.3%) | 18.7% | - | - | - |
| % EBITDA Margin | 51.8% | 47.6% | 69.6% | 62.7% | 60.0% | 54.3% | 49.4% | 21.3% | (13.1%) | 28.5% | - | - | - |
| NET Income (USD) | 15,436,738,471 | 14,303,535,937 | 43,627,867,915 | 42,292,784,528 | 59,231,019,516 | 73,166,705,232 | 69,765,654,196 | 25,149,968,451 | (30,038,850,866) | 93,262,649,042 | - | - | - |
| % Net Margin | 42.6% | 36.5% | 57.5% | 47.8% | 44.4% | 40.4% | 34.0% | 12.2% | (21.3%) | 50.4% | - | - | - |
Medytox - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Medytox | - | ||||||||
| PIPE | Completed | Medytox | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.